Ascend Therapeutics US will be the exclusive seller and marketer of Aevum Life Science's Protiva Pregnancy and Protiva New Mom / Recover products across the US, under an agreement signed between the two companies.

The products are useful for improving quality of life for women during pregnancy and post-delivery.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Canadian biopharmaceutical company Aeterna Zentaris intends to issue shares of its common stock in order to raise $50m in gross proceeds.

The proceeds are intended to be used for general corporate purposes.

Tyme Technologies has raised $8.15m through the private placement of 3.1 million shares to a group of private investors.

See Also:

The proceeds are intended to be used for initiating Phase II clinical trial in pancreatic cancer and build out its operating structure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Tyme Technologies has raised $8.15m through the private placement of 3.1 million shares to a group of private investors."

Based in the US, the company is focused on cancer therapeutics.

US-based biopharmaceutical company Axsome Therapeutics intends to offer shares of its common stock to public through underwriters, who will have a 30-day option to purchase up to an additional 15% of the shares.

The proceeds are intended to fund the company’s ongoing clinical trials, and for working capital and general corporate purposes. The remaining funds will be invested in short-term, investment-grade, interest-bearing instruments and US government securities.

La Jolla Pharmaceutical Company, also a biopharmaceutical company based in the US, intends to raise $100m through a similar offering.

The proceeds are intended to be used for general corporate purposes.